Showing results (111-120 of 169) with videos related to
Sort By:
Pageof 17
Psychological Medicine|June 11, 2020
Motivational and cognitive factors linked to community integration in homeless veterans: study 1 - individuals with psychotic disordersMichael F Green, Jonathan K Wynn, Sonya Gabrielian, et al.Community Mental Health Journal|July 27, 2010
Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERIAlexander S Young, Noosha Niv, Matthew Chinman, et al.The American Journal of Psychiatry|March 22, 2017
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive DyskinesiaRobert A Hauser, Stewart A Factor, Stephen R Marder, et al.Schizophrenia Research|July 31, 2007
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trialJonathan K Wynn, Michael F Green, Joyce Sprock, et al.Schizophrenia Bulletin|September 28, 2013
Adapting social neuroscience measures for schizophrenia clinical trials, part 3: fathoming external validityCharles M Olbert, David L Penn, Robert S Kern, et al.Schizophrenia Bulletin|November 16, 2017
Understanding the Association Between Negative Symptoms and Performance on Effort-Based Decision-Making Tasks: The Importance of Defeatist Performance BeliefsL Felice Reddy, William P Horan, Deanna M Barch, et al.Journal of Clinical Psychopharmacology|November 6, 2019
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive DyskinesiaStephen R Marder, Carlos Singer, Jean-Pierre Lindenmayer, et al.Journal of Clinical Pharmacology|January 18, 2008
Sex, race, and smoking impact olanzapine exposureKristin L Bigos, Bruce G Pollock, Kim C Coley, et al.The Journal of Clinical Psychiatry|September 22, 2021
PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly Extended-Release Risperidone) in Schizophrenia PatientsAnne Le Moigne, John Csernansky, Robert A Leadbetter, et al.The Journal of Clinical Psychiatry|November 13, 2009
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapyJohn M Kane, Christoph U Correll, Donald C Goff, et al.Pageof 17